Disruptive Technology Channel ARKG Leads in 1-Week Returns as Biotech Rebounds By Elle CarusoJune 29, 2022
Expert Insights Chart of the Week: Advisors Remain Confident in Disruptive Innovation By Todd RosenbluthJune 23, 2022
Disruptive Technology Channel Get Exposure to the Genomic Revolution With ARKG By Elle CarusoJune 9, 2022
Disruptive Technology Channel An Innovative ETF Opportunity That Taps Into Our Increased Understanding of the Human Genome By Max ChenJune 8, 2022
Disruptive Technology Channel Change the DNA of Your Portfolio: Growth Opportunities Through Genomics By Max ChenJune 7, 2022
Disruptive Technology Channel Investors Flock to ARKK; Fund Sees $658 Million in May Inflows By Elle CarusoJune 3, 2022
Disruptive Technology Channel Some ARKG Components Could Lead in Genetic Testing By Tom LydonJune 1, 2022
Disruptive Technology Channel Why Investors Should Consider ETFs That Target Innovation Platforms By Max ChenApril 27, 2022
Disruptive Technology Channel Refining Your Innovation Exposure: How to Access Tomorrow’s Opportunities By Max ChenApril 26, 2022
Disruptive Technology Channel One of ARK Invest’s Favorite Stocks Offers Big Rebound Potential By Tom LydonApril 8, 2022
Disruptive Technology Channel Disruptive Tech ETFs Rally on Encouraging Dialogue Between Russia and Ukraine By Max ChenMarch 29, 2022
Disruptive Technology Channel Teladoc Endorsement Could Be Positive for This ETF By Tom LydonFebruary 14, 2022
Disruptive Technology Channel Volatility Is Not a Bad Word With a Long-Term Time Horizon By Max ChenFebruary 4, 2022
Disruptive Technology Channel A Bright Outlook for Gene Editing Investing By Tom LydonFebruary 2, 2022
Disruptive Technology Channel Gene Editing Stocks Might Be Building Some Momentum By Tom LydonJanuary 12, 2022
Disruptive Technology Channel Pfizer/Beam Deal Highlights In Vivo Potential By Tom LydonJanuary 11, 2022
